Deliver logo
Previous Sponsor
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
As a trusted tool provider for clinicians and industry, from large to small, CliniMACS® Systems provide technologies and instruments to the clinic. From immuno-oncology, regenerative medicine, to graft engineering, you’ll find comprehensive solutions for numerous clinical settings.
Using CliniMACS Systems, cell products have been manufactured for all stages of clinical development - from discovery to IND submission and ongoing clinical trials. We are committed to supporting investigators with solutions that enable the clinical translation and practice of novel cell and gene therapies. This support includes products and services that extend the value beyond the device and consumables.
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.​​ Together with our customers, we unlock the potential of blood and cellular therapies to enable better lives
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With over 180 experts focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit https://ct.catapult.org.uk.
Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.
Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in life sciences instruments and solutions used at the forefront of important areas of investigation, including genomics, proteomics and cellular research.
金西盟国际集团是一家全球性细胞技术公司,专注低温细胞医学、细胞治疗、干细胞治疗,在美国、欧洲 以及亚洲都有自己的工厂、研发机构和分公司,1995年进入中国,并成立了金西盟中国公司、工厂及研发机构。
金西盟拥有全球最先进的细胞自动化分离制备、细胞自动化培养扩增、细胞自动化存储、细胞工厂自动化 设备、试剂以及耗材的研发生产基地。
技术领先、性能稳定,是金西盟征战全球的核心竞争力!
目前金西盟已经成为全球三大,亚洲最大的气相液氮罐生产厂家,在中国细胞治疗、干细胞、生物样本库、精子库等领域都拥有最高的市场占有率!
Website:
Werum IT Solutions is the world’s leading supplier of manufacturing execution systems (MES) and manufacturing IT solutions for the pharmaceutical and biopharmaceutical industries. Its PAS-X software product is run by the majority of the world’s top 30 pharmaceutical and biotech companies and also by many mid-sized manufacturers.
Werum is working side by side with many of the commercial pioneers in the fast growing cell and gene therapy sector focusing on managing the complex processes involved in the manufacturing and transport of these personalized medicines.
Werum’s manufacturing IT solutions help pharma manufacturers to increase efficiency, improve productivity, and meet regulatory requirements. Founded in 1969, Werum is headquartered in Lüneburg, Germany, and has many locations in Europe, America, and Asia.
Werum is part of Medipak Systems, the Pharma Systems business area of the international technology group Körber. The Körber group unites around 12,000 professionals in industry-leading companies worldwide, achieving annual earnings of 2.6 billion Euros.
德国维隆是为制药和生物医药行业提供生产执行系统(MES)及制造IT解决方案全球优秀的供应商。其完备即用的PAS-X软件产品被世界排名前30位的大多数制药和生物技术公司以及许多中型制药企业所采用。维隆的制造IT解决方案帮助制药企业提高效率、提高生产力并满足法规要求。项目范围包括在全世界多个站点推出的全球MES项目,以及在各个国家执行的单一站点解决方案。
MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs in a broad range of conditions. MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, and has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy and regenerative medicine space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.
With 25 years of experience we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.
CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products are used to help care for critically and chronically ill patients. The people of Fresenius Kabi are driven by a common purpose to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face
Fresenius Kabi develops advanced transfusion medicine, cell therapy, infusion, and clinical nutrition technologies that help to increase the impact of donors and collectors in blood and plasma centers, scale the discoveries of researchers in biotechnology labs, and expand patient treatment options and enhance drug administration safety in acute care facilities.
Fresenius Kabi is dedicated to working with cell therapy labs of all sizes and stages to create cell processing systems to address the industry’s biggest research and manufacturing challenges, from process development to full commercialization.
Applitech pharmaceutical Equipment Technology Co.Ltd is Applikon Biotechnology BV’s China office which is a privately owned Dutch company developing, manufacturing and supplying bioreactor systems for both research and production use. In the laboratory bioreactor and fermentor range Applikon is worldwide market leader because of its dependable and easy to use systems.
Applitech is based on the optimization, amplification and industrilization of Biological process. In order to have a perfect product line, We also introduced the most advanced technologies and products, such as Kaiser Raman spectrometer, Nova Biochemical analyzer , Constant Systems high pressure cell disrupter and so on, providing comprehensive and professional products solutions in Biopharmaceutical or cell therapy industries.
At present , Applitech has offices in Guangzhou, Beijing, Shanghai, Chengdu, xi 'an with experienced technical support team and big after-sale service team. We can provide the best technology applications service and a full range of professional technical services & solutions for the bio-pharmaceutical customers.
典奥生物科技(上海、香港、台湾)成立于1994年。公司以国际一流仪器生厂商为背景,为国内生命科学研究机构和医药研发创新公司提供国际一流水平的仪器设备软硬件和技术服务平台。
作为生命科学仪器设备的顶级供应商,典奥生物以使用者的角度筛选出业界最好的产品,派遣专业的工程师至原厂进行最严格的考察,以具有丰富研发经验的专家为技术支持,专业的维修团队为服务后盾,为客户提供最前沿的技术支持和高质量的服务保障。
多年来,典奥生物以专业的产品和服务获得了业内广泛的认可和好评。今后,典奥生物也会以一贯的严谨态度,持续走在生命科学领域研究市场的最前端,将最前沿的技术及时分享给大家。
1990年成立,专业从事生命科学和医学领域的高端仪器及试剂的综合性商贸公司。目前,在北京、上海和广州等城市开设了分公司,组建了一支高水平的服务团队,具备生命科学大型设备销售、技术支持和售后维修的全链条服务能力。 近年来,积极布局精准医学、合成生物学和细胞治疗领域创新性的前沿技术,聚焦于声波式高通量移液技术、单分子技术、微流体芯片、数字化定量与高灵敏多重检测技术在精准医学和合成生物学领域中应用。公司总代理美国Maxcyte公司Maxcyte GT临床级大容量流式电转系统,美国FDA认证的知名品牌NanoString nCounter荧光条码多重核酸检测系统,美国Labcyte公司ECHO声波非接触移液工作站,JN Medsys公司Clarity数字PCR系统等。与大中华地区科技界和医学界的众多科研、生产及医疗单位建立了广泛业务关系,在生物医学领域赢得了很高声誉。
Shanghai XP Biomed Ltd. was found in Shanghai, Zhangjiang Hi-tech park in 2005.
XP Biomed focus on cell culture, supplying high quality reagents and optimized protocols for cell therapy, 3D culture and exosome research for R&D studies and clinical settings. We also provide service for cell authentication, cell senescence, mycoplasma detection etc.
XP Biomed and Israel BIOLOGICAL INDUSTRIES jointly established BI (Shanghai) Ltd which has built a GMP factory. The Quality Management System was certified by TÜV for ISO 9001:2008 and ISO 13485:2012.
Healthgen Biotechnology Corp. (Healthgen Biotech) is a private company founded in 2006. We are focusing on developing, manufacturing and marketing a series of environmental friendly and safe products by using the State-of-the-Art platform called OryzHiExp, having high capacity to express proteins or small peptides in the rice grain.
Using the OryzHiExp platform, Healthgen Biotech maximizes the innovative animal-free product development opportunities for clients and partners. Its cost-effective expression capability made it as a breakthrough expression platform.Healthgen Biotech has achievements in developing and commercializing products, such as OsrHSA, OsrbFGF, OsrIGF-1, OsrEGF, OsrLF, OsrAAT.
Healthgen Biotech’s Quality Control System has been certified by ISO 9001: 2008 and ensures standardized process as well as qualified products. Our scale production facility is compliant with GMP. All products can be used as the cell culture media supplements, industrial biological reagents in bio-pharmaceuticals processing and life science researches.
和元生物技术(上海)股份有限公是一家国内领先的专注于质粒和病毒的基础研究(CRO)、非注册临床研究(ITT)、临床申报(CDMO)和GMP产业化服务为一体的高新技术企业。公司拥有近1万平米的工艺研发实验室,质控实验室,中试车间和GMP生产车间。技术团队平均拥有超过10年的生物制药经验,在质粒、AAV病毒、慢病毒和各种融瘤积累了大量的项目经验。
Obio is a leading high-tech enterprise in Shanghai, focusing on plasmid and virus one-stop services, from lab scale CRO, Investigator initiated trail (ITT), Gene therapy drug IND (CDMO) to GMP grade manufacturing (CMO). Company already established 10000m2 facility, including PD lab, QC lab, pilot plant, and GMP site. The technical team has more than 10 years biopharma industry experience, and has completed several gene therapy projects covering plasmid, AAV, Lentivirus, and different oncology viruses in past three years.
“艾力特”自成立以来,一直致力于为生命科学和生物技术行业提供先进的仪器设备,技术以及服务。坚持不断提升产品创新性和客户价值,构建了完善的产品体系,除自主研发的Countstar细胞分析仪外,还是多家欧美生物设备供应商在中国的合作伙伴。为客户提供从研发到生产的各类实验室仪器,检测试剂和生产设备。公司客户主要为中国领先的生物制药,细胞治疗,生物医学和各类生物技术公司,以及大量的生命科学基础研究和政府实验室。我们已成为中国生命科学和生物技术行业重要的仪器和设备供应商。在行业和客户中拥有极佳的口碑。
Since its inception, Alit has been providing advanced equipment, technology and services to the life sciences and biotechnology industries. We insist on improving product innovation and customer value to build a complete product supply system. In addition to the self-developed Countstar cell analyzer, we are also a partner of many European and American bio-equipment suppliers in China. Providing customers with all kinds of laboratory instruments, testing reagents and production equipment from R&D to manufacture. The company's customers are mainly China's leading biopharmaceutical, cell therapy, biomedical and various biotechnology companies, as well as a large number of life science basic research laboratory and government research institution. We have become an important supplier of instruments and equipment for the life sciences and biotechnology industries in China and have an excellent reputation in the industry.
公司创建于2005年,总部和研发中心设于上海,在欧洲,北京,广州,成都设有办事处。十余年来,坚持理想,不忘初心。以“创新改变未来,为科技进步加油”为己任,在全球化的今天,坚持全球研发,全球销售,中国生产。已经获得中国,美国和日本授权的多项发明专利。不断的为生命科学的产业化发展提供最有价值的产品和技术解决方案。
The company was founded in 2005, with headquarters and R&D center in Shanghai, and offices in Europe, Beijing, Guangzhou and Chengdu. For more than ten years, I have adhered to our ideals and have not forgotten our original aspiration. With the faith of “innovation to change the future”, we adhere to global R&D and Chinese production. Until now, it has obtained a number of invention patents authorized by China, the United States and Japan. And we will continuously provide the most valuable products and technical solutions for the industrialization of life sciences.
我们在“商业不是最首要的目的,最重要的是提升自己,利益他人,幸福世界”经营原则下,相信我们团队存在的价值和我们的客户一样:为人类带来关爱!面向未来,所有“艾力特”人将继续发挥积累多年的专业优势,为客户提供高品质,高价值的创新性产品和技术解决方案。
Our motto is “Business is not our first purpose, but the most important thing is to improve ourselves and benefit others”. We believe that our team has the same value as our customers, which is bringing the happiness to the world. To face the future, all “Alit” people will continue to develop their professional skills by accumulated over the years of experience to provide customers with high quality service, high value innovative products and technical solutions.
Polyplus-transfection ® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in France, Polyplus-transfection® applies it’s 17+ year expertise to the development of novel transfection solutions for mammalian cells. We provide reagents for high yield transient protein and antibody production in CHO and HEK-293 cells, as well as for viral vector production for Gene and Cell Therapy (PEIpro product range). Our products meet the quality requirements for use in bioprocesses up to GMP grade.
Charles River Laboratories, Inc. is a leading contract research service provider. We help accelerate drug development by supporting our clients’ research every step of the way. Microbial Solutions is one of the business segments of Charles River. We’ve purposely built our portfolio to bring you progressive products and services that deliver accurate, relevant, and reliable data to fuel confident decisions on product quality and contamination control. We lead the market with products and services that meet the diverse needs of the pharmaceutical, home, beauty, dairy, beverage, and food industries. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
普瑞金——成立于2012年,是国家中小企业发展基金和中国科学院投资的高新技术企业。公司深耕于CAR-T细胞药物领域,拥有一支学术背景深厚、实践经验丰富的科研及产业化团队,分别在北京和深圳建有研发平台、CAR-T细胞药物CDMO平台。与国家上海新药安全评价研究中心达成战略合作,参与起草中检院2018年6月发布的《CART细胞质量控制检测研究及非临床评价考虑要点》。 普瑞金已实现多个CAR-T细胞药物的IND申报,现已打造全面符合IND申报标准的质粒、病毒、CAR-T细胞制备的全流程工艺及质量控制体系,使产品开发周期可控、产业化生产成本极具优势。
AUSTAR Lifesciences Limited (the“Company”), together with its subsidiaries (collectively as the "Group") are a leading provider of integrated engineering solutions with high-end and comprehensive services and products to reputable pharmaceutical manufacturers and research institutes in the PRC and also a provider of the services and products to customers in emerging countries. On 7 November 2014 , the Company (Stock code: 6118) was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Group was founded in 1991 with its headquarter based at Beijing, PRC. We can assist our customers in key phases of pharmaceutical product lifecycle. We, together with our joint ventures, also engage in the manufacture, sale and distribution of various types of high-end pharmaceutical equipment and life science consumables, we offer a variety of quality products in our product portfolio to our customers.
达科为生物(Dakewe Biotech Co., Ltd.)成立于1999年,是国内一流的民营生物高科技企业,现已形成以深圳为总部,在北京、上海、广州、成都、武汉、香港等十余城市设有分支机构的集团性企业公司。
主要业务涉及生物科学(BioScinece)和生物医学(BioMedicine)两大细分领域,包括生命科学研究用仪器(Scientific Instruments)和试剂(Life Science Reagents)、医疗设备(Medical Equipments)和诊断试剂(Diagnostic Reagents)等产品和技术的研发、生产及营销推广。
公司现与国外百余家生物科技公司和国内数千家客户保持着良好的业务合作关系,产品已远销至台湾,东南亚,欧洲,北美等地。公司先后被认定为“深圳市高新技术企业”、“深圳市民营科技企业”和“深圳市南山区科技孵化企业”等,主要研发项目受到国家科技部、深圳市科技局和南山区科技局的大力扶持和资助。
Website: www.porton.cn
Porton Pharma Solutions Ltd. (former name: Porton Fine Chemicals Ltd) founded in 2005, is a top-tier CDMO, providing services to the global pharmaceutical industry with intergraded research, development and manufacturing of custom drug intermediates and APIs.
We operate three Process R&D Centers, and three Manufacturing Sites across China, and leading US based CRO J-Star with expertise in GMP/GLP synthesis, Crystallization research and High potent handling etc.
Supported by >1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across China, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates.
Ask Us How We Can Help You @ www.porton.cn
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
GigaCeuticals Co., Ltd. is aiming at accelerating drug discovery by combining various technologies, including artificial intelligence, systems biology and big data. GigaCeuticals offers prediction, validation and design of small molecule drugs in a multiple purposes fashion against aging related diseases, metabolic diseases and other chronic diseases, which lack of explicit targets or involving a multiple targets mechanism. Currently, the experimentally validated model, at animal level, including extending longevity, anti-obesity, treating hyperuricemia and anti-oxidant / fibrosis.
There are several ways we offer services: i) we predict and validate clients’ self-owned drug-like library using validated model and return top-hit list with experimental reports. ii) We co-develop novel small molecules against certain disease with CRO companies. iii) We sell or license IPs. Other models are under validation including NAFLD/NASH, epilepsy, stem cell renewal, tendon healing, cancer, immunity boost, Alzheimer’s’ disease and etc.
The small molecules we developed has followed properties: i) comparable or better effect than known drugs (first / best-in-class), ii) multiple candidates with similar effects, iii) with multiple purposes, like treating hyperuricemia and anti-fibrosis, iv) with less ADRs. v) continually designing candidates until fulfill all needs, vi) go with novel targets / mechanisms identified.
JenKem Technology is dedicated to the development and supply of PEG-based products and custom PEGylation services, with worldwide distribution, and the recent significant addition of new R&D through commercial scale GMP facilities.
Development and manufacture of a wide range of PEG derivatives with high purity and low polydispersity, currently in 1 gram to 40 kg or greater sized batches, under ISO 9001 and ISO 13485 certified Quality Management Systems, following ICH Q7A guidelines and operating under cGMP protocols for regulated customers. Custom synthesis of Y-Shaped PEGs, Methoxy PEGs, Homobifunctional PEGs, Heterobifunctional PEGs, Multi-arm PEGs, Multi-arm Heterobifunctional PEGs, Monodisperse (Discrete) PEGs, Biodegradable PEG Co-Polymers (such as PEG-PLGA, PEG-PLA, PEG-PCL, and other block polymers), and PEG GPC Standards.
Custom PEGylation of proteins, peptides, oligonucleotides, and small molecules; and conjugation of PEGs to other polymer systems. Large scale manufacturing on a custom synthesis basis, which offers the flexibility to match a customer’s specifications.
Website:www.cas.org
CAS, a division of the American Chemical Society, is dedicated to the ACS vision of improving people's lives through the transforming power of chemistry. The CAS team of highly trained scientists identifies, aggregates, and organizes all publicly disclosed chemistry information, creating the world's most valuable collection of content that is vital to innovation worldwide. Scientific researchers, patent professionals and business leaders around the world rely on a suite of research solutions from CAS that enables discovery and facilitates workflows to fuel tomorrow’s innovation. Flagship solutions include SciFinder®, SciFindern, and STNextTM.
北京海金格医药科技股份有限公司(股票代码:834524)成立于2006年,是一家专注提供临床研究技术服务公司。其主要业务涉及化学创新药临床研究(Ⅰ-Ⅳ期)、生物制品创新药临床研究(Ⅰ-Ⅳ期)、中药及天然药物创新药临床研究(Ⅰ-Ⅳ期)、医疗器械临床研究、生物等效性(BE)及药代动力学(PK/PD)临床研究、化学药一致性评价临床研究、化学仿制药临床研究、中药及化学药注射剂上市后再评价临床研究及学术推广、第三方稽查服务、数据管理与统计分析服务、SMO服务、受试者招募服务、进口药注册服务、特殊医学食品注册及临床研究、临床批件及生产批件技术转让、GCP及法规培训服务、临床研究机构第三方认证培训服务等。
Website: www.e-3.com
E3 was founded by a group of veterans from the pharmaceutical industry determined to solve the serious problems with laboratory safety and energy-efficiency.
The advent of E3's patented breakthrough innovations, the Bernoulli Laminar Air-Curtain Containment Hood and SmartFlow Damper System, has brought forth a solution for the age-long global dilemma of having to compromise between laboratory safety and energy efficiency.
The Bernoulli Hood delivers exceptional "zero-spill" containment safety performance while simultaneous providing unparalleled energy efficiency of up to 80%. With the Bernoulli Hood, laboratory owners can enjoy an unprecedented level of worker safety and HVAC energy cost reduction, drastically reducing their laboratory carbon footprint to achieve an unforeseen level of sustainability.
The Bernoulli SmartFlow Damper System is the most compact and simplified airflow control solution in the world. With an accuracy of over 95% and a response time of less than 2.5 seconds, it is also the first and only product to control airflow through direct real-time measurement of flowrate. Its integrated and patented multi-vane technology eliminates the complexities and costs associated with airflow testing, adjusting and balancing work.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai. As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise. Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 36 patent attorneys is in the top tier of China, and our firm enjoys a patent grant rate of over 90% for invention in such areas. For three consecutive years (2015-2017), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
LexOrbis is one of the most recommended full service IP firms in India with offices at 3 locations namely, New Delhi, Mumbai and Bangalore. We have a strong team of over 65 attorneys including 46 patent attorneys having expertise in the field of mechanical, electronics, wireless communication, software, mobile applications, chemistry, biotechnology, etc. who are involved in drafting new patent applications originating from India and filing and prosecuting international patent applications. A team of over 19 lawyers at our firm also have deep expertise in handling trademark prosecution and contentious cases. Our patent and trademark attorneys work in combination with our IP litigators to handle a large number contentious IP cases such as pre-and post- grant oppositions, cancellation and infringement suits and criminal enforcement of India rights in India.
Founded in 2011, we provide small molecule process development and manufacturing services to the pharmaceutical industry.
We evaluate our clients needs and provide creative solutions to deliver valuable, enabling compounds from small quantities of unique compounds to support early and pre-clinical development, to large volumes of key intermediates for clinical studies and commercial supply. In addition to all the chemistries you would expect from a world class small molecule developer, we have specialized expertise in developing chiral compounds, unnatural amino acids, and sulphur containing molecules.
Raffles operates 40,000 sq. ft of modern, well-equipped facilities across two sites in Guangdong, and a business development and technical support function in Philadelphia.
Help Stem Cell Innovations is a leading clinical-stage biotechnology company in Nanjing, China, dedicating to the development of next-generation cell-based therapeutics for degenerative diseases. Our first-in-class cell therapy candidates undergoing clinical development utilize human induced pluripotent stem cells (iPSC) generated from our proprietary iPSC platform. By restoring function, these next-generation medicines have the potential to revolutionize current treatment paradigm.
Human iPSC also represents a powerful platform for drug discovery and efficacy evaluation. Assessment of drug safety and efficacy is complex and time consuming. We support our customers by providing high quality, standardized human iPSC-derived cardiomyocytes and neural cells specially designed for drug screening. Together with our customized high-throughput assays, our stem cell products effectively decrease drug attrition rate and costs in drug development processes.
Beijing HFK Bioscience Co. Ltd. (HFK) was founded in 2008 in conjunction with theInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, in Changping District, Beijing, China. HFK is dedicated to developing and providing laboratory animals, animal models for human diseases,laboratory animal diets and related services.HFK's success results from its large group of experienced researchers and innovative elite with its high emphasis on quality. The quality of its products and services is beijing maintained by this large and dedicated research group and consultant team comprised
by international and domestic experts in the field of laboratory animal science. HFK consists of four branches: the Laboratory Animal Resources (LAR), the Laboratory Animal Diets (LAD), the Research and Development (R&D) and Quality Assurance Unit(QAU).
◆The LAR provides more than 1,000,000 SPF rodents annually, including 200 strains of spontaneous and genetically engineered animal models for human diseases.
◆The LAD owns an automated manufacturing system with the capability to produce 5,000 tons of a wide array of high quality diets per year, including specialformulated diets for all kinds of laboratory animal. All diets are in compliance with GLP standards.
◆The R&D offers the service for generating animal models for human diseases,including the surgical, chemical or diet induced, transgenic, gene knock-in or gene knock-out animal models. Cryopreservation and cryorecovery services are alsoavailable.
◆The QAU is independent of other branches, with advanced equipments and a well trained team. The unit is responsible for running the ISO9001 quality management system of the company.
We look forward to working with you to provide you with your basic research needs. We are dedicated to provide you the utmost in quality and price.
Website: www.tzcmc.net
China Medical City (Taizhou National Medical High-tech Zone) is located in Taizhou City, Jiangsu Province. As the first national level life science hi-tech Park, China Medical City (CMC) is jointly built by Ministry of Science and Technology, China Food and Drug Administration (CFDA), National Health and Family Planning Commission, China Administration of Traditional Chinese Medicine and Jiangsu Provincial Government. Jiangsu CFDA CMC Branch, Jiangsu Food and Drug Inspection Institute CMC Branch, Jiangsu Medical Device Testing Center CMC Branch have been established successively to better support the industry and offer services to the companies more efficiently.
We are committed to building the largest life scienceindustrial base with the most integrated industrial chainin China. China Medical City has cooperated with over 50 famous life science R&D institutes domestic and abroad, and there are over 900 companies including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi-Pasteur, and Takeda in China Medical City.
China Medical City, a new city for life science industryin China, your first choice for investment!
Asia Pharma R&D Leaders Summit 2019  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© Asia Pharma R&D Leaders Summit 2019 – All rights reserved